1 / 55

Peter J Voshol, PhD Director of Disease Model Core

Disease Model Core Metabolic Phenotyping: which parameters do we (or need to) measure in Glucose Handling?. Peter J Voshol, PhD Director of Disease Model Core Senior Research Associate: Integrative Physiology.

winona
Download Presentation

Peter J Voshol, PhD Director of Disease Model Core

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Disease Model Core Metabolic Phenotyping: which parameters do we (or need to) measure in Glucose Handling? Peter J Voshol, PhD Director of Disease Model Core Senior Research Associate: Integrative Physiology

  2. Disease Model Core Metabolic Phenotyping: which parameters do we (or need to) measure in Glucose Handling? • Discuss the following: • Glucose-phenotyping: Using CD36-/- as example • Discussing specific considerations and methods • Suggestion for SOP guides for phenotyping

  3. CD36…??? • Fatty acid translocase, also known as CD36: • A receptor for several ligands, including oxidized LDL and long chain fatty acids. • CD36 is abundant in peripheral tissues active in fatty acid metabolism, such as adipose tissue and skeletal and cardiac muscle, where it is involved in high-affinity uptake of fatty acids.

  4. CD36, fatty acid translocator: Knockout leads to altered disposition of FFA’s

  5. What about Glucose Metabolism?

  6. Higher insulin sensitivity during a ITT (fixed dose) on chow fed mice.

  7. What about a GTT?

  8. The dose is important: Am J Physiol Endocrinol Metab 297: E849–E855, 2009.

  9. What about our HFD model in real life?

  10. Same dose of glucose with ~10g BW difference:

  11. The effect is in Insulin!

  12. The AUC calculated and corrected for baseline values.

  13. Is there a difference IP of ORAL GTT?

  14. Effect of fasting on baseline glucose and insulin levels:

  15. Effect of fasting on GTT: glucose and insulin levels: Am J Physiol Endocrinol Metab 295:E1323-E1332, 2008.

  16. Same dose of glucose with ~10g BW difference:

  17. The effect is in Insulin!

  18. Similar to Human CLAMP:

  19. Insulin Insulin - + X The principles of a CLAMP: More glucose infusion = higher insulin sensitivity index Exogenous glucose infusion Plasma Compartment Hepatic glucose production Peripheral tissues glucose uptake (euglycemic)

  20. The principles of a CLAMP:

  21. 2 1 Sensitive Resistant Severe resistance Insulin resistance? 120 100 80 60 Effect (%) 40 20 0 0 5 10 15 Insulin concentration

  22. 120 100 80 Effect (%) 60 40 EGP 20 BGU 0 0 2 4 6 8 10 12 Insulin concentration Differences in tissue-specific insulin sensitivity:

  23. Factual clamp data showing the main tissues: Periphery Adipose tissue Liver Am J Physiol Endocrinol Metab 291: E1360–E1364, 2006.

  24. The basic CLAMP (no tracer kinetics)

  25. The tracer kinetic CLAMP

  26. Principle of tracer dilution

  27. Remember the kinetics:

  28. The calculations:

  29. Insulin-stimulated tracer dilution

  30. Insulin-stimulated kinetics:

  31. Changes in blood tracer dilutions:

  32. A word on Euglycemia: Normal concentration of glucose in the blood. Also called normoglycemia. The ‘normal’ or baseline fasted glucose concentration measured in your mouse model!

  33. Euglycemic

  34. That is why choosing your infusion insulin concentration is very important:

  35. That is why choosing your infusion insulin concentration is very important:

  36. That is why choosing your infusion insulin concentration is very important:

  37. Double tracer CLAMP, tissue specific glucose uptake:

  38. 2-Deoxy glucose as glucose tracer:

  39. Other analyses possible during CLAMP:

  40. That is why choosing your infusion insulin concentration is very important: Conclusions: Insulin = 3 GIR control = 80 µmol/min GIR model X = 45 µmol/min Model X is insulin resistant compared to controls!!! Insulin = 6 GIR control = 100 µmol/min Gir model x = 100 µmol/min Model X has equal insulin sensitivity compared to control!!!

  41. Example: Diabetes 55:390–397, 2006

  42. Example Diabetes 55:390–397, 2006

  43. And fasting has an effect of course: Mice get peripheral insulin sensitivity upon fasting!

  44. Background breeding effect: Diabetes 57:1790–1799, 2008

  45. Back to CD36-/- mouse model: Improved peripheral glucose metabolism J.Lipid Res. 2003. 44: 2270–2277.

  46. CD36-/-: But decreased hepatic insulin sensitivity.

  47. CD36-/-: Due to TG accumulation in CD36-/- mice

  48. Conclusion on glucose metabolism in CD36-/- mice:

  49. What SOP can be suggested to run: • Lipid metabolism • Glucose metabolism • Energy balance

  50. Basal lipid-phenotyping

More Related